HRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Heron Therapeutics Inc (HRTX) is not a good buy for a beginner, long-term investor at this time. The stock's technical indicators, options data, financial performance, and lack of positive catalysts do not support a strong investment case. Additionally, the company's financials show declining revenue, net income, and EPS, which are red flags for long-term growth potential.
The MACD histogram is positive but contracting, indicating weakening momentum. RSI is neutral at 72.004, and moving averages are converging, showing no clear trend. Key resistance is at 0.952, and support is at 0.788. Overall, the technical indicators suggest a lack of strong upward momentum.
NULL. There are no recent news events, no significant insider or hedge fund activity, and no recent congress trading data to act as positive catalysts.
Declining financial performance with revenue, net income, and EPS all showing significant YoY drops. The stock trend analysis suggests a 7.81% potential decline in the next month. Additionally, the lack of recent AI Stock Picker or SwingMax signals further diminishes the investment case.
In Q4 2025, revenue dropped by -0.47% YoY to $40.59M. Net income fell by -180.64% YoY to -$2.95M, and EPS declined by -200.00% YoY to -0.02. Gross margin also decreased by -3.08% YoY to 72.61. These metrics indicate poor financial health and declining growth trends.
No recent analyst rating or price target changes are available for HRTX.
